ClinicalTrials.gg
CompletedNCT03172598Updated Dec 22, 2025

Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy

A Phase 2 interventional study of MT-8554 low dose and MT-8554 middle dose in Painful Diabetic Peripheral Neuropathy, sponsored by Tanabe Pharma Corporation. Completed at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Tanabe Pharma Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A Study to Investigate the Safety, Tolerability and Efficacy of Multiple Doses of MT-8554 in Subjects with Painful Diabetic Peripheral Neuropathy

02

Conditions studied

  • Painful Diabetic Peripheral Neuropathy
03

In context

Lead sponsor

Tanabe Pharma Corporation is the lead sponsor of 92 studies on the registry; 1 is open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male subjects and female subjects aged ≥18 years
  • Subjects who have a history of pain at least 6 months and ≤7 years attributed to diabetic peripheral neuropathy
  • A ranging from 18 to 45 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Subjects who have participated in a clinical study of any IMP (other than placebo) within 12 weeks (from last administration) prior to screening or who are currently participation in another clinical study
  • Unstable or uncontrolled diabetes
  • 12-lead abnormalities
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    MT-8554 low dose

    Patients who meet eligibility criteria will be administered twice daily low dose of MT-8554 during the treatment period.

    Drug: MT-8554 low dose

  • Experimental
    MT-8554 middle dose

    Patients who meet eligibility criteria will be administered twice daily middle dose of MT-8554 during the treatment period.

    Drug: MT-8554 middle dose

  • Experimental
    MT-8554 high dose

    Patients who meet eligibility criteria will be administered twice daily high dose of MT-8554 during the treatment period.

    Drug: MT-8554 high dose

  • Experimental
    MT-8554, then placebo

    The study participants will receive MT-8554 (TBD mg) in the first phase, followed by placebo in the second phase

    Drug: MT-8554 low dose · Drug: MT-8554 middle dose · Drug: MT-8554 high dose · Drug: Placebo

  • Experimental
    Placebo, then MT-8554

    The study participants will receive placebo in the first phase, followed by MT-8554 (TBD mg) in the second phase

    Drug: MT-8554 low dose · Drug: MT-8554 middle dose · Drug: MT-8554 high dose · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability as measured by vital signs and Adverse Events

    Number of participants with potentially clinically important vital sign measurements or tolerability issues

    Time frame: Up to Day 22

  2. Efficacy as measured by reduction in pain using a numerical rating scale.

    Pain reduction using an 11-point numerical rating scale

    Time frame: Up to Day 49

Secondary outcomes

  1. Number of subjects with electrocardiogram (ECG) findings of potential clinical importance

    Number of participants with potentially clinically important ECG findings

    Time frame: Up to Day 49

  2. Plasma concentration of MT-8554

    Maximum Observed Plasma Concentration (Cmax)

    Time frame: Up to Day 49

07

Study locations

3 sites
  • Investigational center
    City Name, Germany
  • Investigational center
    City Name, Hungary
  • Investigational center
    City Name, Poland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in Aug 2018, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2017
First posted
Jun 1, 2017
StartActual
Jul 25, 2017
Primary completionActual
Aug 8, 2018
CompletionActual
Aug 8, 2018
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03172598
Responsible party
Sponsor
First posted
Jun 1, 2017
Start date
Jul 25, 2017
Primary completion
Aug 8, 2018
Completion
Aug 8, 2018
Last update
Dec 22, 2025

Study contacts

General Manager
study director · Tanabe Pharma Europe Ltd

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elismetrep

Start the discussion